Evaluation of bivalent human papillomavirus (HPV) vaccine safety and tolerability in a sample of 25 year old Tuscan women

References

• Trottier H, Burchell AN. Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics 2009; 12:291 - 307; http://dx.doi.org/10.1159/000214920; PMID: 19684442
   PubMed Web of Science ®Google Scholar
• Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM, ALTS Group. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007; 195:1582 - 9; http://dx.doi.org/10.1086/516784; PMID: 17471427
   PubMed Web of Science ®Google Scholar
• Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244 - 65; http://dx.doi.org/10.1136/jcp.55.4.244; PMID: 11919208
   PubMed Web of Science ®Google Scholar
• Srodon M, Stoler MH, Baber GB, Kurman RJ. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol 2006; 30:1513 - 8; http://dx.doi.org/10.1097/01.pas.0000213291.96401.48; PMID: 17122506
   PubMed Web of Science ®Google Scholar
• Kayes O, Ahmed HU, Arya M, Minhas S. Molecular and genetic pathways in penile cancer. Lancet Oncol 2007; 8:420 - 9; http://dx.doi.org/10.1016/S1470-2045(07)70137-7; PMID: 17466899
   PubMed Web of Science ®Google Scholar
• Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001; 345:1890 - 900; http://dx.doi.org/10.1056/NEJMra001375; PMID: 11756581
   PubMed Web of Science ®Google Scholar
• Herrero R, Castellsagué X, Pawlita M, Lissowska J, Kee F, Balaram P, et al, IARC Multicenter Oral Cancer Study Group. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003; 95:1772 - 83; http://dx.doi.org/10.1093/jnci/djg107; PMID: 14652239
   PubMed Web of Science ®Google Scholar
• Cupp MR, Malek RS, Goellner JR, Espy MJ, Smith TF. Detection of human papillomavirus DNA in primary squamous cell carcinoma of the male urethra. Urology 1996; 48:551 - 5; http://dx.doi.org/10.1016/S0090-4295(96)00246-4; PMID: 8886059
   PubMedGoogle Scholar
• D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356:1944 - 56; http://dx.doi.org/10.1056/NEJMoa065497; PMID: 17494927
   PubMed Web of Science ®Google Scholar
• Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005 p; 6:204 - 204; http://dx.doi.org/10.1016/S1470-2045(05)70086-3; PMID: 15830458
   PubMed Web of Science ®Google Scholar
• von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001; 11:598 - 603, quiz 604; PMID: 11701422
   PubMed Web of Science ®Google Scholar
• Ministero della Salute. Sessione XLVI, sessioni congiunte II e III. Seduta dell’11 Gennaio 2007.
   Google Scholar
• Gasparini R, Bonanni P, Levi M, Bechini A, Boccalini S, Tiscione E, et al. Safety and tolerability of bivalent HPV vaccine: an Italian post-licensure study. Hum Vaccin 2011; 7:Suppl 136 - 46; http://dx.doi.org/10.4161/hv.7.0.14576; PMID: 21266842
   PubMed Web of Science ®Google Scholar
• Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, et al, GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374:1975 - 85; http://dx.doi.org/10.1016/S0140-6736(09)61567-1; PMID: 19962185
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, et al, HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161 - 70; http://dx.doi.org/10.1016/S0140-6736(07)60946-5; PMID: 17602732
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow S-N, Apter D, et al, HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301 - 14; http://dx.doi.org/10.1016/S0140-6736(09)61248-4; PMID: 19586656
   PubMed Web of Science ®Google Scholar
• Keam SJ, Harper DM. Human Papillomavirus Types 16 and Adjuvanted, Adsorbed) [ Cervarix TM ]. 2008;68(3):359–72.
   Google Scholar
• Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T. Safety of human papillomavirus (HPV) -16 / 18 AS04-adjuvanted vaccine for cervical cancer prevention. 2009;5(5):332–40.
   Google Scholar
• Verstraeten T, Descamps D, David M-P, Zahaf T, Hardt K, Izurieta P, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008; 26:6630 - 8; http://dx.doi.org/10.1016/j.vaccine.2008.09.049; PMID: 18845199
   PubMed Web of Science ®Google Scholar
• MHRA. Suspected Adverse Reaction Analysis CERVARIX Human papillomavirus (HPV) vaccine 29 July 2010.
   Google Scholar
• Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, et al, HPV Study Group for Adult Women. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009; 27:581 - 7; http://dx.doi.org/10.1016/j.vaccine.2008.10.088; PMID: 19022320
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al, HPV-010 Study Group. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009; 5:705 - 19; http://dx.doi.org/10.4161/hv.5.10.9518; PMID: 19684472
   PubMed Web of Science ®Google Scholar
• Petäjä T, Keränen H, Karppa T, Kawa A, Lantela S, Siitari-Mattila M, et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 2009; 44:33 - 40; http://dx.doi.org/10.1016/j.jadohealth.2008.10.002; PMID: 19101456
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Procedural steps taken and scientific information after the authorisation 2009.
   Google Scholar